ROCKET PHARMACEUTICALS, INC. - 8-K Filing
Rocket Pharmaceuticals reported $144.4 million in cash, cash equivalents, and investments as of March 31, 2026 (excluding PRV monetization), with pro forma balances reaching approximately $322.6 million after a non-dilutive $180 million sale of its Rare Pediatric Disease Priority Review Voucher. R&D expenses were $31.5 million for Q1 2026, down from $35.9 million in the same period last year due to reduced manufacturing and headcount costs; G&A expenses fell to $17.1 million versus $28.4 million a year ago. The company expects its cash runway to extend into Q2 2028. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $RCKT